Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Antihypertensive effects of SGLT2 inhibitors in type 2 diabetes.

× No keyword cloud information.

10 in total

Review 1. Molecular Mechanisms Underlying the Cardiovascular Benefits of SGLT2i and GLP-1RA.

Authors: Dorrin Zarrin Khat; Mansoor Husain
Journal: Curr Diab Rep Date: 2018-06-09 Impact factor: 4.810

Review 2. Ambulatory Blood Pressure Reduction With SGLT-2 Inhibitors: Dose-Response Meta-analysis and Comparative Evaluation With Low-Dose Hydrochlorothiazide.

Authors: Panagiotis I Georgianos; Rajiv Agarwal
Journal: Diabetes Care Date: 2019-04 Impact factor: 19.112

Review 3. The impact of oral anti-diabetic medications on heart failure: lessons learned from preclinical studies.

Authors: Vaia Lambadiari; George Dimitriadis; Nikolaos P E Kadoglou
Journal: Heart Fail Rev Date: 2018-05 Impact factor: 4.214

Review 4. SGLT2 Inhibition in the Diabetic Kidney-From Mechanisms to Clinical Outcome.

Authors: Erik J M van Bommel; Marcel H A Muskiet; Lennart Tonneijck; Mark H H Kramer; Max Nieuwdorp; Daniel H van Raalte
Journal: Clin J Am Soc Nephrol Date: 2017-03-02 Impact factor: 8.237

5. Effects of 6 Months of Dapagliflozin Treatment on Metabolic Profile and Endothelial Cell Dysfunction for Obese Type 2 Diabetes Mellitus Patients without Atherosclerotic Cardiovascular Disease.

Authors: Ju-Young Hong; Keun-Young Park; Jong-Dai Kim; Won-Min Hwang; Dong-Mee Lim
Journal: J Obes Metab Syndr Date: 2020-09-30

6. A Pilot Study Embedding Clinical Pharmacists Within an Interprofessional Nephrology Clinic for the Initiation and Monitoring of Empagliflozin in Diabetic Kidney Disease.

Authors: Laura K Triantafylidis; Chelsea E Hawley; Christopher Fagbote; Jiahua Li; Nicole Genovese; Julie M Paik
Journal: J Pharm Pract Date: 2019-09-24

Review 7. SGLT-2 Inhibitors and Cardiovascular Protection: Lessons and Gaps in Understanding the Current Outcome Trials and Possible Benefits of Combining SGLT-2 Inhibitors With GLP-1 Agonists.

Authors: Elamin Abdelgadir; Fauzia Rashid; Alaaeldin Bashier; Razan Ali
Journal: J Clin Med Res Date: 2018-06-27

8. Glycemic Efficacy and Metabolic Consequences of an Empagliflozin Add-on versus Conventional Dose-Increasing Strategy in Patients with Type 2 Diabetes Inadequately Controlled by Metformin and Sulfonylurea.

Authors: Yujin Shin; Ji Hye Moon; Ho Jun Chin; Ele Ferrannini; Soo Lim
Journal: Endocrinol Metab (Seoul) Date: 2020-06-24

Review 9. New Diabetes Therapies and Diabetic Kidney Disease Progression: the Role of SGLT-2 Inhibitors.

Authors: Claire C J Dekkers; Ron T Gansevoort; Hiddo J L Heerspink
Journal: Curr Diab Rep Date: 2018-03-27 Impact factor: 4.810

10. Effect of Hemoglobin A1c Reduction or Weight Reduction on Blood Pressure in Glucagon-Like Peptide-1 Receptor Agonist and Sodium-Glucose Cotransporter-2 Inhibitor Treatment in Type 2 Diabetes Mellitus: A Meta-Analysis.

Authors: Mengdie Hu; Xiaoling Cai; Wenjia Yang; Simin Zhang; Lin Nie; Linong Ji
Journal: J Am Heart Assoc Date: 2020-03-30 Impact factor: 5.501

10 in total